



(51) International Patent Classification:

C07K 19/00 (2006.01) *A61K 39/395* (2006.01)
C07K 14/505 (2006.01) *C12N 1/21* (2006.01)
C12N 15/62 (2006.01) *G01N 33/50* (2006.01)
A61K 39/00 (2006.01) *C07K 14/475* (2006.01)
C07K 16/00 (2006.01) *C12N 15/13* (2006.01)
C12N 15/70 (2006.01)

(21) International Application Number:

PCT/US2010/024546

(22) International Filing Date:

18 February 2010 (18.02.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/208,487 24 February 2009 (24.02.2009) US

(71) Applicant (for all designated States except US): **ALEX-
ION PHARMACEUTICALS, INC.** [US/US]; 352
Knotter Drive, Cheshire, CT 06410 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SPRINGHORN,
Jeremy, P.** [US/US]; 150 Innonwood Road, Guilford, CT
06437 (US). **GIES, David** [US/US]; 43 Stoddard Place,
Beacon Falls, CT 06403 (US).

(74) Agents: **VARMA, Anita** et al.; Ropes & Gray LLP, One
International Place, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES

(57) Abstract: The present disclosure features therapeutic antibodies (e.g., TPO mimetic antibodies) and therapeutically-active fragments thereof as well as methods for preparing and using the antibodies and fragments. For example, the therapeutic antibodies and their fragments are useful in a variety of diagnostic and/or therapeutic applications such as methods for increasing platelet levels in a subject.

